Metsera, Inc. aims to raise $275 million in an IPO to fund its clinical-stage biopharma programs targeting obesity and ...

Co., Inc. (NYSE:MRK), a global healthcare leader, declared on Monday a quarterly dividend and a substantial stock repurchase ...

This has hurt major AI players led by chipmaker Nvidia ( NVDA) , as the innovation threatens the demand for Nvidia's ...

Merck said its board authorized an additional $10 billion share repurchase authorization, which has no time limit for completion. The maker of medicines and vaccines has a market cap of $247.75 ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that the Board of Directors has ...

Healthcare stocks are widely considered a cornerstone of a retirement portfolio due to their resilience, long-term growth ...

Exelixis (EXEL) has recently gained traction in the rapidly growing oncology market with its promising pipeline and strong ...

Analyst downgrades Salesforce to a sell rating due to slowing growth in key segments and AI posing a risk to revenue model.

We recently published a list of Kevin O’Leary’s Stock Portfolio: 15 Stock Picks for 2025. In this article, we are going to ...

Lockheed Martin’s fourth-quarter earnings per share topped expectations, while the top line disappointed. The outlook was mixed, as well.

Merck (MRK) is expected to deliver a year-over-year increase in earnings on higher revenues when it reports results for the quarter ended December 2024. This widely-known consensus outlook gives a ...

When Merck reports fourth-quarter earnings, investors are likely to focus on the sales of its blockbuster oncology medicine, ...